Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 45801-45810 Newer>

The Motley Fool December 3, 2010 Seth Jayson	Why Marvell Technology Group's Earnings Are Outstanding With 10.3% of operating cash flow coming from questionable sources, Marvell Technology Group investors should take a closer look at the underlying numbers.
The Motley Fool December 3, 2010 Toby Shute	A-Power Gets A-nnihilated The Chinese alt-energy player comes up way short in its latest quarterly report.
The Motley Fool December 3, 2010 Seth Jayson	Don't Get Too Worked Up Over Brocade Communications Systems' Earnings With 38.2% of operating cash flow coming from questionable sources, Brocade Communications Systems investors should take a closer look at the underlying numbers.
The Motley Fool December 3, 2010 Seth Jayson	Here's How Applied Materials Is Making You So Much Cash With 14.6% of operating cash flow coming from questionable sources, investors in the semiconductor maker should take a closer look at the underlying numbers.
The Motley Fool December 3, 2010 Seth Jayson	If You See This, Should You Sell JDS Uniphase? For the last fully reported fiscal quarter, JDS Uniphase's year-over-year revenue grew 36.1%, and its AR grew 54.7%. That's a yellow flag.
The Motley Fool December 3, 2010 Jeremy Phillips	Time to Sell Ceragon Networks? Let's evaluate the price, valuation, margins, and liquidity of the communications equipment company.
The Motley Fool December 3, 2010 Anders Bylund	Does Avago Have Room to Grow? Communications chip designer Avago Technologies delivered a fine but unimpressive fourth quarter, but what they do best is to generate cash.
The Motley Fool December 3, 2010 Anders Bylund	Finisar Leads the Charge of the Light Brigade Optical component maker Finisar came through with a terrific second-quarter report, beating expectations and guiding even higher for the next quarter.
The Motley Fool December 3, 2010 Christopher Barker	Miners on the Move: Fronteer Gold The story behind gold and silver's superstars.
The Motley Fool December 3, 2010 Brian Orelli	Obesity Drug Companies Are (Still) Risky Orexigen heads before an FDA panel.
<Older 45801-45810 Newer> Return to current articles.